Here are your 2 Elite stocks for the day. These are our top growth/momentum picks we are watching at the moment.

If you have any questions, please contact me at [email protected].

If you’ve received any value from our picks, we’d really appreciate it if you could take 1 minute to leave us a review on Trustpilot.

It helps us reach more traders, grow the community, and keep delivering more value for everyone.

Please help us out!

1 Year Chart:

Buy Level:

Looking to accumulate in the $50 range, which lines up with recent support levels in the area.

Category: Growth

Market Cap: $2.1B

Company Info:

Celcuity Inc (NASDAQ: CELC) is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, with a primary emphasis on oncogenic drivers and cellular signaling pathways. Its lead drug candidate, Gedatolisib, is a dual inhibitor of PI3K/mTOR currently in Phase 2 trials for treating HR+/HER2- breast cancer.

Why it’s a buy:

The stock is a buy in 2025 because Celcuity has a promising late-stage asset in Gedatolisib that could address a multi-billion-dollar breast cancer market with limited effective options. The drug’s dual-action mechanism targets a pathway often implicated in treatment resistance, giving it a strong scientific rationale.

The company also has a solid cash runway to advance trials without near-term dilution and a history of partnerships with top research institutions. With positive early clinical data, a clear regulatory pathway, and a major unmet need in its target indication, Celcuity offers a compelling asymmetric upside as a high-risk, high-reward biotech with strong fundamentals.

1 Year Chart:

Buy Level:

Looking to accumulate in the $3 – $3.10 range. This stock is on the first day of it’s run. Dip buying into support is strong, however be aware this is a volatile stock.

Category: Momentum

Market Cap: $978M

Company Info:

Precigen, Inc. (NASDAQ: PGEN) is a clinical-stage biotechnology company specializing in gene and cell therapies to treat cancer and rare diseases. Its proprietary UltraCAR-T platform and ActoBiotics technology aim to deliver more precise, regulated, and cost-effective therapies compared to traditional approaches.

Why it’s a buy:

The stock is a buy in 2025 because Precigen is making meaningful progress in its oncology pipeline, especially with PRGN-3006, a non-viral CAR-T therapy targeting AML (acute myeloid leukemia), which has shown encouraging clinical responses in early trials. Unlike conventional CAR-T therapies, UltraCAR-T is designed for rapid, single-day manufacturing, which could radically reduce both treatment time and cost — solving a major bottleneck in the cell therapy space.

With a diverse pipeline, a strong IP portfolio, and upcoming clinical milestones across multiple assets, Precigen offers a high-upside opportunity in the race to develop next-generation immunotherapies.

If you haven’t already, check out our Elite watchlist updated every week:

This is also available in the elite discord.

The #1 Trading Software in the world: Tradingview

As always you are more then welcome to send me an email at [email protected] or DM me on instagram @crowntradingllc if you have any questions about the market or stock opportunities.

If you would like to see specific statistics about the companies in these newsletters reach out to me with your suggestions!

Thank you for reading!

Jordan K.

Disclaimer: The stocks mentioned in this email do not represent the exact positions of Crown Trading, but rather ideas and opportunities we are currently monitoring. Just because a stock is featured here does not mean we own or are actively trading it. The buy levels are not recommendations. This is not financial advice, and neither myself nor Crown Trading is recommending that you buy or sell any securities. All information is for educational purposes only and should not be relied upon for investment decisions. Please do your own research before making any trades.